Autoimmune diabetes

Probiotic-based therapy for autoimmune diabetes: Probiotic  Dulac ATP increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 10/March/2019, 1.47 pm
Probiotic-based therapy for autoimmune diabetes: Probiotic  Dulac ATP increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 10/March/2019, 1.47 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical Sciences, University of Milan, Milan…

read more

Probiotic-based therapy for autoimmune diabetes: Probiotic Bifidobacterium infantis increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 7/March/2019, 11,44 pm
Probiotic-based therapy for autoimmune diabetes: Probiotic Bifidobacterium infantis increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 7/March/2019, 11,44 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical Sciences, University of Milan, Milan…

read more

Molecular therapy for autoimmune diabetes (TIDM): Extendin-4(brand name: Byetta, Bydureon, Exenatide), a GLP-1 receptor agonist, increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 5/March/2019, 5.59 pm
Molecular therapy for autoimmune diabetes (TIDM): Extendin-4(brand name: Byetta, Bydureon, Exenatide), a GLP-1 receptor agonist, increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 5/March/2019, 5.59 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical Sciences, University of…

read more

Ribonucleic acid-based therapy for Diabetes Mellitus: LncRNA CACS15 augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIDM via upregulation of its target gene, 25/February/2019, 1.34 am
Ribonucleic acid-based therapy for Diabetes Mellitus: LncRNA CACS15 augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIDM via upregulation of its target gene, 25/February/2019, 1.34 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say  A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection of FGF1 induces sustained…

read more

Molecular therapy for Autoimmune diabetes:XBP-1  increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 20/February/2019, 12.30 am
Molecular therapy for Autoimmune diabetes:XBP-1  increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 20/February/2019, 12.30 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical Sciences, University of Milan, Milan…

read more

Molecular therapy for Autoimmune diabetes: Valproic acid (trade name: Convulex, Depakote, Epilim, Stavzor), used to treat  seizures and bipolar disorder,  increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 19/February/2019, 11.55 pm
Molecular therapy for Autoimmune diabetes: Valproic acid (trade name: Convulex, Depakote, Epilim, Stavzor), used to treat  seizures and bipolar disorder,  increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 19/February/2019, 11.55 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical Sciences, University of Milan, Milan…

read more
Start Typing